TRION Pharma GmbH

TRION Pharma is a biopharmaceutical company that develops trifunctional antibodies called Triomab® at its site in Munich.

They are based on a platform technology for which TRION Pharma holds IP rights around the world. Triomab® antibodies simultaneously activate multiple immune defence mechanisms against cancer. As a result, tumour cells are specifically destroyed with hitherto unknown potency and precision, and the immune system's memory is activated.
 
In 2009, Removab® (Catumaxomab) was the first member of the Triomab® family to receive EU market approval. It is not only the first drug indicated for the treatment of malignant ascites (abdominal fluid retention) in cancer patients, but also the first bispecific, trifunctional antibody worldwide. Removab® is marketed by TRION's development partner Fresenius Biotech.